Evidence map›Paper›PMID 39710753›Full record

ArticleCardiology and therapy2025

Patient Characteristics and Real-World Treatment of Very Elderly Patients with Nonvalvular Atrial Fibrillation in Japan: An Administrative Claims Database Study.

Ako Matsuo-Ohsawa, Jun Katada

Abstract read
In one paragraph

Article in Cardiology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ako Matsuo-OhsawaInternal Medicine Medical Affairs, Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-Ku, Tokyo, 151-8589, Japan. ako.ohsawa@pfizer.com.ORCID http://orcid.org/0009-0006-0855-2602
Jun KatadaInternal Medicine Medical Affairs, Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-Ku, Tokyo, 151-8589, Japan.ORCID http://orcid.org/0000-0003-3588-3686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVery elderly patients with nonvalvular atrial fibrillation (NVAF) are at high risk for both ischemic and hemorrhagic events. This study aimed to understand the characteristics and real-world treatment of very elderly patients with NVAF in Japan.

methodsWe conducted a retrospective analysis of electronic health records and claims data from acute care hospitals for very elderly patients with NVAF with medical records available on or after their 80th birthday. The outcomes of interest were (1) characteristics of very elderly patients and (2) patterns of anticoagulation and impact of clinical condition on anticoagulation.

resultsOf 1,278,404 patients with newly diagnosed atrial fibrillation (AF), 443,820 were eligible for the analysis. Mean ± standard deviation age was 84.5 ± 5.5 years, CHADS

conclusionsA significant proportion of very elderly patients with NVAF in Japan were diagnosed with NVAF after the age of 80 years and were not receiving anticoagulation therapy, particularly with increasing age. Furthermore, warfarin use declined with age, and patients on DOACs frequently received reduced doses.

Indexed as

Anticoagulation therapyNonvalvular atrial fibrillationVery elderly

Identifiers

PMID39710753
PMCPMC11893952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.